Track topics on Twitter Track topics that are important to you
AMES, Iowa, July 24, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing novel immuno-oncology and infectious-disease products to improve the lives of patients, reported that it will release its second quarter 2015 financial results on Friday, July 31, 2015. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.
NewLink’s senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.
Access to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 94565879. The replay will be available for two weeks from the date of the call.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve the lives of patients with cancer. Our portfolio of product candidates is poised to further cancer-treatment research. NewLink Genetics is actively researching a unique, multifaceted immuno-oncology treatment strategy based on its HyperAcute® Immunotherapies, which are designed to educate patients’ natural defenses to target cancer directly, and IDO Pathway Inhibitors, which act either alone or in combination with other treatment options to prevent tumor cells from evading the immune response. NewLink’s Ebola vaccine candidate is being tested in advanced clinical trials in Africa. For more information, please visit http://www.newlinkgenetics.com.
Corporate Contact: Jack Henneman, Chief Financial Officer 515-598-2561 Investor@Linkp.com Investors: Donna LaVoie or Kristina Coppola LaVoieHealthScience 617-374-8800 X105/7 Media: David Connolly LaVoieHealthScience 617-374-8800 X108 firstname.lastname@example.orgNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...